BLOG / 🇺🇸 United States · · daily

Contract Option Exercises — September 22, 2026

Contract Option Exercises

By Gunpowder Editorial ·

1 total filings analysed

Executive Summary

This digest covers a single contract option exercise from September 22, 2026, totaling $240.6 million, entirely civilian (Department of Veterans Affairs) with no defense-related awards. The dominant theme is sustained VA spending on medical evaluation services, with the highest-conviction signal being Leidos Holdings' subsidiary QTC Medical Services winning a competitive, firm-fixed-price delivery order that is 97% funded.

Key risk: the contract's one-year term ended September 2024, and no follow-on awards are visible in this data, creating a revenue gap risk for Leidos if the VA does not re-compete or extend the work.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior Contract Option Exercises digest from September 20, 2026.

Investment Signals (2)

  • Leidos faces revenue cliff as QTC Medical Services' $240.6M VA contract nears completion (MEDIUM)
    ▲

    The $240.6 million firm-fixed-price delivery order to QTC Medical Services (Leidos subsidiary) from the VA for medical evaluation services has a one-year performance period ending September 30, 2024, with 97% of funds already outlayed. No options or follow-on contracts are included in this data, creating a potential revenue gap for Leidos if the VA does not re-compete or extend the work.

  • Leidos' competitive win signals strong positioning in VA medical evaluation market (MEDIUM)
    ▲

    QTC Medical Services won this $240.6 million contract under full and open competition with no set-aside, indicating a competitive moat in physician-based evaluation/screening services (NAICS 621111). The near-complete funding utilization (97%) suggests high demand and reliable execution, which could lead to future task orders or re-competes.

Risk Flags (2)

  • Concentration [HIGH RISK]
    ▼

    Leidos' QTC subsidiary is highly dependent on VA medical evaluation contracts; this single $240.6M award represents a material revenue stream with no visible follow-on in the data.

  • Budget [MEDIUM RISK]
    ▼

    The VA's medical evaluation budget is subject to annual appropriations; a government shutdown or continuing resolution could delay or reduce follow-on awards for QTC/Leidos.

Opportunities (1)

  • ◆

    The VA's sustained spending on medical evaluations (evidenced by 97% funding utilization) suggests stable or growing demand for physician-based screening services, benefiting Leidos and other contractors like Maximus or General Dynamics Health.

Sector Themes (1)

  • ◆

    The VA's $240.6 million award to QTC Medical Services for physician-based evaluations, with 97% funding utilization, demonstrates strong demand for outsourced medical screening services despite broader budget uncertainty.

Watch List (2)

  • 👁

    {"entity" => "Leidos Holdings (LDOS)", "reason" => "QTC Medical Services subsidiary faces revenue gap risk after September 2024 contract end; no follow-on visible in this data.", "trigger" => "VA announcement of re-compete or extension for medical evaluation services"}

  • 👁

    {"entity" => "VA healthcare services sector", "reason" => "This contract signals stable demand for outsourced medical evaluations; watch for budget shifts or telehealth expansion.", "trigger" => "FY2025 VA budget proposal or NDAA provisions affecting medical services procurement"}

Get daily alerts with 2 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: Contract Option Exercises

🇺🇸 More from United States

View all →